Acute Coronary Syndrome (ACS) continues to be a significant cause of morbidity and mortality worldwide. Despite advances in medical technology, the management of ACS remains complex. Optimizing patient outcomes necessitates an integrated approach that combines state-of-the-art diagnostic modalities, risk stratification techniques, and advanced therapeutic strategies.
Early and accurate diagnosis is pivotal in ACS management. High-sensitivity cardiac troponin assays have revolutionized the diagnostic landscape of ACS, enabling earlier detection of myocardial injury. Furthermore, the incorporation of advanced imaging techniques such as coronary computed tomography angiography (CCTA) can provide detailed insights into coronary anatomy and plaque characteristics, facilitating more personalized treatment strategies.
Risk stratification plays a crucial role in guiding therapeutic decisions in ACS. The GRACE and TIMI risk scores are widely used for this purpose. However, newer risk stratification tools such as the PRECISE-DAPT score can provide additional information on bleeding risk, which is particularly relevant when considering dual antiplatelet therapy.
Therapeutic strategies in ACS have evolved significantly over the years. Current guidelines recommend early invasive strategy in high-risk patients. Pharmacotherapy, including dual antiplatelet therapy and statins, remain the cornerstone of ACS management. Additionally, the emergence of novel antiplatelet agents and PCSK9 inhibitors has expanded the therapeutic armamentarium. Furthermore, the role of non-pharmacological interventions such as cardiac rehabilitation and lifestyle modifications in improving long-term outcomes cannot be overemphasized.
In conclusion, optimizing patient outcomes in ACS requires a comprehensive approach that integrates advanced diagnostic modalities, risk stratification techniques, and therapeutic strategies. Continued research and innovation in these areas are essential to further improve patient outcomes and reduce the burden of ACS.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation